TY  - CHAP
U1  - Buchbeitrag
A1  - Schuhmacher, Alexander
A1  - Gassmann, Oliver
A1  - Hinder, Markus
ED  - Schuhmacher, Alexander
T1  - A review of the pharmaceutical R&D efficiency : costs, timelines, and probabilities
T2  - Value creation in the pharmaceutical industry : the critical path to innovation
N2  - It is known that the costs related with drug research and development (R&D) and the timelines to develop a new drug increased over the past years. In parallel, the success rates of drug projects along the pharmaceutical R&D phases are still very low, and the outcome of all R&D efforts is stagnating. In consequence, the R&D efficiency defined as the financial investment per drug has been steadily decreasing. As innovation is the major growth driver of the pharmaceutical industry, reliable data on R&D efficiency and new concepts to overcome these challenges are of great interest for R&D managers and the sustainability of the pharmaceutical industry as a whole. This book chapter reviews publications on R&D performance indicators of the past years, such as the success rates and timelines per phase. Additionally, it illustrates the factors influencing the success rates, timelines, and costs of pharmaceutical R&D most and, thus, the denominators of the R&D efficiency.
KW  - R&D efficiency
KW  - success rates of pharmaceutical R&D
KW  - costs of drug development
KW  - R&D timelines
Y1  - 2016
SN  - 978-3-527-69340-5
SB  - 978-3-527-69340-5
U6  - https://doi.org/10.1002/9783527693405.ch4
DO  - https://doi.org/10.1002/9783527693405.ch4
SP  - 61
EP  - 79
S1  - 19
PB  - Wiley
CY  - Weinheim
ER  -